Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat in previously treated MDS
NCT01902381Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of devimistat in myelodysplastic syndrome (MDS), sponsored by Wake Forest University Health Sciences. Primary endpoint: Response Rate at 5 years. Started Aug 2013; status: terminated.
02
Drugs
devimistat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01902381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01902381.